EasySep™ Human B Cell Isolation Kit

Immunomagnetic negative isolation of untouched human B cells

EasySep™ Human B Cell Isolation Kit

Immunomagnetic negative isolation of untouched human B cells

From: 980 USD
Catalog #
(Select a product)
Immunomagnetic negative isolation of untouched human B cells
Add to Wish List

Product Advantages


  • Fast, easy-to-use and column-free

  • Up to 96% purity with high recovery

  • Isolated cells are untouched

What's Included

  • EasySep™ Human B Cell Isolation Kit (Catalog #17954)
    • EasySep™ Human B Cell Isolation Cocktail, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
    • EasySep™ Isolation Cocktail Enhancer, 1 mL
  • EasySep™ Human B Cell Isolation Kit (Catalog #100-0971)
    • EasySep™ Human B Cell Isolation Cocktail, 1 x 10 mL (Catalog #300-0510)
    • EasySep™ Isolation Cocktail Enhancer, 1 x 10 mL (Catalog #300-0511)
    • EasySep™ Dextran RapidSpheres™, 1 x 10 mL (Catalog #300-0380)
  • RoboSep™ Human B Cell Isolation Kit (Catalog #17954RF)
    • EasySep™ Human B Cell Isolation Cocktail, 1 mL
    • EasySep™ Dextran RapidSpheres™, 1 mL
    • EasySep™ Isolation Cocktail Enhancer, 1 mL
    • RoboSep™ Buffer (Catalog #20104)
    • RoboSep™ Filter Tips (Catalog #20125)
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

Overview

Easily and efficiently isolate highly purified human B cells from fresh or previously frozen human peripheral blood mononuclear cells (PBMCs) or washed leukapheresis samples by immunomagnetic negative selection, with the EasySep™ Human B Cell Isolation Kit. Widely used in published research for more than 20 years, EasySep™ combines the specificity of monoclonal antibodies with the simplicity of a column-free magnetic system.

In this EasySep™ negative selection procedure, unwanted cells are labeled with antibody complexes and magnetic particles. Unwanted cells expressing the following markers are targeted for removal: CD2, CD3, CD14, CD16, CD36, CD43, CD56, CD66b, and GlyA. The magnetically labeled cells are then separated from the untouched desired human B cells by using an EasySep™ magnet and simply pouring or pipetting the desired cells into a new tube. Following magnetic cell isolation in as little as 9 minutes, the desired B cells are ready for downstream applications such as flow cytometry, culture, or DNA/RNA extraction.

This product replaces EasySep™ Human B Cell Enrichment Kit (Catalog #19054) for even faster cell isolations.

For large-scale isolation of human B cells from leukapheresis samples, see the large-format (1x10^10 cells) kit (Catalog #100-0971).

Learn more about how immunomagnetic EasySep™ technology works or how to fully automate immunomagnetic cell isolation with RoboSep™. Alternatively, choose ready-to-use, ethically sourced, primary Human Peripheral Blood B Cells, Fresh isolated with EasySep™ Human B Cell Isolation Kit. Explore additional products optimized for your workflow, including culture media, supplements, antibodies, and more.
Magnet Compatibility
• EasySep™ Magnet (Catalog #18000)
• “The Big Easy” EasySep™ Magnet (Catalog #18001)
• Easy 50 EasySep™ Magnet (Catalog #18002)
• EasyEights™ EasySep™ Magnet (Catalog #18103)
• RoboSep™-S (Catalog #21000)
• Easy 250 EasySep™ Magnet (Catalog #100-0821)
Subtype
Cell Isolation Kits
Cell Type
B Cells
Species
Human
Sample Source
Leukapheresis, PBMC
Selection Method
Negative
Application
Cell Isolation
Brand
EasySep, RoboSep
Area of Interest
Chimerism, HLA, Immunology

Data Figures

Figure 1. Typical EasySep™ Human B Cell Isolation Profile

Starting with human PBMCs, the B cell (CD3-CD19+) content of the isolated fraction is typically 95.1 ± 1.4% (mean ± SD). In the example above, the final purities of the start and isolated fractions are 4.5% and 94.9%, respectively.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
100-0971
Lot #
All
Language
English
Catalog #
17954
Lot #
All
Language
English
Catalog #
17954RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
100-0971
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
100-0971
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17954
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17954
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17954
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17954RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17954RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17954RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
17954RF
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Frequently Asked Questions

Can EasySep™ be used for either positive or negative selection?

Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).

How does the separation work?

Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.

Which columns do I use?

The EasySep™ procedure is column-free. That's right - no columns!

How can I analyze the purity of my enriched sample?

The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.

Can EasySep™ separations be automated?

Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.

Can EasySep™ be used to isolate rare cells?

Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 µL. Samples containing 2x107 cells or fewer should be suspended in 100 µL of buffer.

Are the EasySep™ magnetic particles FACS-compatible?

Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.

Can the EasySep™ magnetic particles be removed after enrichment?

No, but due to the small size of these particles, they will not interfere with downstream applications.

Can I alter the separation time in the magnet?

Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.

For positive selection, can I perform more than 3 separations to increase purity?

Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

How does the binding of the EasySep™ magnetic particle affect the cells? is the function of positively selected cells altered by the bound particles?

Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.

If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.

Publications (38)

Engineering Human Donor Derived Germinal Center-Like Organoids (GCLOs) for Studying Immune Response to Vaccination. B. Suthar et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026 Jul

Abstract

Germinal centers (GCs) are transient microanatomical structures that coordinate humoral immune responses through dynamic interactions between antigen presenting cells, T follicular helper cells, and B cells. Despite their central importance to immune protection, GC human biology remains difficult to interrogate due to significant inter-species variability, limited experimental accessibility to primary human tissues, and high interindividual variability. We developed a human immune culture platform that supports spontaneous multicellular organization of human peripheral blood mononuclear cells derived from primary CD19+ B cells, memory CD4+ T cells, and monocyte-derived dendritic cells into Germinal Center-like Organoids (GCLOs). These bioengineered GCLOs self-organize into stable clusters that exhibit stimulus and donor dependent differences in cellular composition and function. We observed the emergence of GC-like T and B cell subsets, functional IgG output, and the appearance of plasmablast-like populations. Notably, the age of the donors and the type of stimuli influenced GCLOs architecture, immune subsets, and antibody output. Platform outputs showed correspondence with clinical vaccine responsiveness across human donors, capturing inter-individual differences in humoral GCLO immune responses to the flu vaccine, including age-associated trends consistent with immunosenescence. This platform allows scalable investigation of human GC-associated immune features and provides a tractable framework for studying donor heterogeneity in humoral immunity.
Chimeric allergen receptor regulatory T cells suppress birch pollen allergic airway inflammation. A. Alcaraz-Serna et al. The Journal of experimental medicine 2026 Aug

Abstract

Asthma is a deadly chronic respiratory disease affecting over 300 million people. While allergen immunotherapy remains the only disease-modifying treatment, it is poorly applicable for patients with severe asthma. Here, we explored the therapeutic potential of regulatory T cells (Tregs) armed with chimeric allergen receptors-named CAlleR-redirected against the major allergen of birch pollen Bet v1. Four novel anti-Bet v1 antibodies were identified and used to engineer and functionally validate CAlleR. CAlleR Tregs showed specific in vitro activation and suppression and significantly reduced the airway hyperresponsiveness in birch pollen-sensitized mice. Mechanistically, CAlleR Tregs migrated to the lungs and mediastinal lymph nodes, interacted with CD11c+ dendritic cells, and were activated in a FcγR-dependent manner by cross-presenting Bet v1 stabilized with noncompetitive anti-Bet v1 antibodies. These findings unveil a novel mechanism for targeting soluble antigens and highlight the potential of CAlleR Tregs to prevent and treat severe allergies.
High Treg and PMN-MDSC densities are a hallmark of tertiary lymphoid structures in fatal cases of cervical cancer L. A. Syding et al. Journal for Immunotherapy of Cancer 2025 Sep

Abstract

BackgroundHigh densities of tertiary lymphoid structures (TLSs) are associated with improved clinical outcomes in various malignancies, including human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC). However, the role of TLSs in shaping antitumor immunity in HPV-induced cervical cancer (CESC) remains unclear. Therefore, we analyzed the density, composition, and prognostic impact of TLSs in patients with CESC as well as patients with HNSCC.MethodsMultiplex immunofluorescence, immunohistochemistry, and spatial transcriptomics were used to analyze TLS density and composition in HNSCC and CESC tissue sections with respect to patient prognosis. The spatial approach was supplemented by flow cytometry-based analysis of the polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) phenotype in freshly resected primary tumor tissues.ResultsAlthough both indications were associated with HPV infection, we confirmed a positive correlation between TLS density and improved overall survival only in patients with HNSCC. The TLS composition differed markedly between HNSCC and CESC samples, with a shift toward high regulatory T cell (Treg) and PMN-MDSC abundance in CESC samples. The highest Treg and PMN-MDSC levels were observed in patients with CESC who died of the disease. CESC-infiltrating PMN-MDSCs showed high arginase 1 expression, which correlated with diminished T-cell receptor (TCR)ζ chain expression in CESC-infiltrating T cells. Additionally, the high number of PMN-MDSCs in TLSs was associated with the absence of HPV-specific T cells in CESC.ConclusionsUnlike in HNSCC, the composition of TLSs, rather than their quantity, was associated with the overall survival of patients with CESC. High numbers of Tregs and PMN-MDSCs infiltrating immature TLSs prevail in patients with CESC who succumbed to the disease and seem to affect tumor-specific immune responses.